Simmons et al., 2018 - Google Patents
TSPO–PET imaging using [18F] PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: Preclinical evidence with the p75NTR …Simmons et al., 2018
View HTML- Document ID
- 11473986935989270799
- Author
- Simmons D
- James M
- Belichenko N
- Semaan S
- Condon C
- Kuan J
- Shuhendler A
- Miao Z
- Chin F
- Longo F
- Publication year
- Publication venue
- Human Molecular Genetics
External Links
Snippet
Huntington's disease (HD) is an inherited neurodegenerative disorder that has no cure. HD therapeutic development would benefit from a non-invasive translatable biomarker to track disease progression and treatment response. A potential biomarker is using positron …
- 201000001971 Huntington's disease 0 title abstract description 153
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Simmons et al. | TSPO–PET imaging using [18F] PBR06 is a potential translatable biomarker for treatment response in Huntington’s disease: Preclinical evidence with the p75NTR ligand LM11A-31 | |
| Zhang et al. | Recent developments on PET radiotracers for TSPO and their applications in neuroimaging | |
| Márquez et al. | Neuroimaging biomarkers for Alzheimer’s disease | |
| Heurling et al. | Synaptic vesicle protein 2A as a potential biomarker in synaptopathies | |
| Varley et al. | Imaging neuroinflammation in Alzheimer's disease and other dementias: recent advances and future directions | |
| Meissner et al. | Multiple system atrophy: recent developments and future perspectives | |
| Bradburn et al. | Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: A meta-analysis | |
| Knezevic et al. | Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment | |
| Sabri et al. | Acetylcholine receptors in dementia and mild cognitive impairment | |
| Niccolini et al. | Neuroimaging in Huntington’s disease | |
| Femminella et al. | Imaging and molecular mechanisms of Alzheimer’s disease: a review | |
| Zhang | Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging | |
| James et al. | [18F] GE-180 PET detects reduced microglia activation after LM11A-31 therapy in a mouse model of Alzheimer's disease | |
| Hirvonen et al. | Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C] WAY-100635 | |
| Thiel et al. | The temporal dynamics of poststroke neuroinflammation: a longitudinal diffusion tensor imaging–guided PET study with 11C-PK11195 in acute subcortical stroke | |
| Femminella et al. | Evaluation of neuroprotective effect of glucagon‐like peptide 1 analogs using neuroimaging | |
| Shah et al. | Molecular imaging insights into neurodegeneration: focus on α-synuclein radiotracers | |
| Harada et al. | Imaging of reactive astrogliosis by positron emission tomography | |
| James et al. | PET imaging of translocator protein (18 kDa) in a mouse model of Alzheimer's disease using N-(2, 5-dimethoxybenzyl)-2-18F-fluoro-N-(2-phenoxyphenyl) acetamide | |
| Beaino et al. | Towards PET imaging of the dynamic phenotypes of microglia | |
| Bauckneht et al. | Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers | |
| Masdeu | Neuroimaging in psychiatric disorders | |
| Benadiba et al. | New molecular targets for PET and SPECT imaging in neurodegenerative diseases | |
| Tremoleda et al. | In vivo PET imaging of the neuroinflammatory response in rat spinal cord injury using the TSPO tracer [18 F] GE-180 and effect of docosahexaenoic acid | |
| Stankoff et al. | Exploring the heterogeneity of MS lesions using positron emission tomography: a reappraisal of their contribution to disability |